Oral small molecule GLP-1 receptor agonist
Vct220 po
VCT220_PO
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.61 (0.29 to 114) | 0.30 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.99 (0.14 to 11.88) | 0.68 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.80 (2.96 to 19.15) | 0.23 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.79 (1.35 to 11.85) | 0.57 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.55 (0.95 to 8.59) | 0.38 |